cisOne or moreagentselected from A/B furostane furostene spirostane and spirostene steroidal sapogenins and ester ether ketone and glycosylated forms thereof including E and/or F ring opened derivatives thereof is used to treat or prevent L DOPA dopamine agonistand/or dopamine enhancer induced disorders such as L DOPA induced dyskinesia (LID) which is a side effect of L DOPA dopamine agonist and/or dopamine enhancer therapies e.g.for Parkinson s disease. The agent according to the invention may be administered in association with the therapeutic agent for the treatment of the Parkinson s disease or another dopamine responsive disorder.
